Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06956235 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
A Phase 2 study of Hidradenitis Suppurativa, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 2
- Development phase
- 147
- Enrollment target
- 20
- Study locations
NCT06956235: Active Phase 2 study of Hidradenitis Suppurativa, sponsored by Merck Sharp & Dohme.
NCT06956235 is a Phase 2 study of Hidradenitis Suppurativa that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 147 participants, below the 595-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06956235, a Phase 2 study of Hidradenitis Suppurativa, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 147 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of participants achieving a 50% reduction in Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16 (ie, at end of double-blind treatment).
Primary Outcome
The percentage of participants with ≥50% reduction in total abscesses and inflammatory nodules (AN) count with no increase in abscess count, and no increase in draining tunnels (ie, HiSCR50) will be reported.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tulisokibart
Study Locations (20)
Texas
- Arlington Center for Dermatology ( Site 0045) - Arlington
- Texas Dermatology Research Center ( Site 0019) - Dallas
- Reveal Research Institute ( Site 0018) - Frisco
- Progressive Clinical Research ( Site 0020) - San Antonio
California
- Northridge Clinical Trials ( Site 0004) - Northridge
- Integrative Skin Science and Research ( Site 0015) - Sacramento
Ohio
- University Hospitals Cleveland Medical Center ( Site 0046) - Cleveland
- Wright State Physicians Health Center ( Site 0041) - Fairborn
Alabama
- Cahaba Dermatology & Skin Health Center ( Site 0012) - Birmingham
Arizona
- Medical Dermatology Specialists ( Site 0027) - Phoenix
Arkansas
- Northwest Arkansas Clinical Trials Center, PLLC ( Site 0049) - Rogers
Florida
- Olympian Clinical Research ( Site 0010) - Tampa
Georgia
- Skin Care Physicians of Georgia ( Site 0033) - Macon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2025-06-09 |
| Est. Completion | 2029-01-22 |
| Phase | Phase 2 |
What the registry record for NCT06956235 still lists
NCT06956235 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 595-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06956235 names 20 study sites across 15 states, led by Texas, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT06956235 about?
NCT06956235 is a clinical study titled "Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)". This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of p...
What is the current status of trial NCT06956235?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2025-06-09. Estimated completion is 2029-01-22.
What conditions does trial NCT06956235 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT06956235?
The interventions under investigation include: Placebo (DRUG), Tulisokibart (DRUG).
Who is sponsoring clinical trial NCT06956235?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06956235 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06956235's enrollment target sits among peer trials
147 26th of 52 higher than 27 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI